From 2024 to 2028, the forecasted sales of antiarrhythmic medicine in Türkiye are expected to remain consistent at 0.1% of total sales annually. The year-on-year variation is 0%, indicating no expected growth or decline during this period. Over the last two years, this stability reflects a lack of significant shifts in market demand or external factors impacting sales metrics. The Compound Annual Growth Rate (CAGR) for the last five years also stands at 0%, reinforcing the trend of stable market performance.
Future trends could include advancements in medical technology and new treatment protocols, which may impact antiarrhythmic medication demand. Additionally, healthcare reforms and economic conditions in Türkiye may alter market dynamics, potentially driving shifts in supply chain and patient access to these medicines.
